Aytu Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary

Aytu Biopharma

12/02/2025 21:50

* Aytu Biopharma Inc  AYTU.OQ  reported a quarterly adjusted
loss
of 26 cents​​ per share for the quarter ended December 31, lower
than the same quarter last year, when the company reported EPS
of -4 cents.  The lone analyst forecast for the quarter was
for a loss of 28 cents per share. 
    * Revenue fell 29.3% to $16.22 million from a year ago;
analysts
expected $15.55 million. 
    * Aytu Biopharma Inc's reported EPS for the quarter was 9
cents​.
    * The company reported quarterly net income of $788
thousand.
    * Aytu Biopharma Inc shares had fallen by 16.5% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 366.7% in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Aytu Biopharma
Inc is $8.00 
This summary was machine generated from LSEG data February 12 at
09:50 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -0.28          -0.26          Beat
 Sep. 30 2024      -0.34          0.44           Beat
 Jun. 30 2024      -0.45          -0.82          Missed
 Mar. 31 2024      -0.64          -0.52          Beat